Alexander D Sherry,Ethan B Ludmir,Pavlos Msaouel
Alexander D Sherry
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201 [0.03%]
艾伏美替尼±达 feedbackorfavir在复发性低级别浆液性卵巢癌中的疗效和安全性：ENGOT-OV60/GOG-3052/RAMP 201主要分析结果
Susana N Banerjee,Els Van Nieuwenhuysen,Carol Aghajanian et al.
Susana N Banerjee et al.
Purpose: This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or in combination with defactinib (focal a...
Regina Barragan-Carrillo,Zeynep B Zengin,Sumanta K Pal
Regina Barragan-Carrillo
The interplay between the human gut microbiome and the immune system has sparked growing interest in microbiome modulation as a therapeutic strategy in oncology. Preclinical studies have identified specific bacterial species linked to impro...
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma [0.03%]
用于可切除黑色素瘤患者的免疫联合新辅助和辅助治疗的长期生存及生物标志物分析：relatlimab(抗LAG-3)和nivolumab(抗PD-1)研究
Elizabeth M Burton,Denái R Milton,Michael T Tetzlaff et al.
Elizabeth M Burton et al.
Immune checkpoint blockade (ICB) has revolutionized outcomes for patients with melanoma across multiple disease settings. In patients with advanced, unresectable disease, the ICB combination of nivolumab (anti-PD1) and relatlimab (anti-LAG-...
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study [0.03%]
一项I期研究中单用divarasilib治疗KRAS G12C阳性非小细胞肺癌患者的长期随访结果
Adrian G Sacher,Wilson H Miller Jr,Manish R Patel et al.
Adrian G Sacher et al.
Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C-positive non-small cell lung c...
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial [0.03%]
产后激素受体阳性乳腺癌的母乳喂养：POSITIVE研究的结果
Fedro A Peccatori,Samuel M Niman,Ann H Partridge et al.
Fedro A Peccatori et al.
Purpose: We investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor-positive (HR+) BC who had a live birth in the POSITIVE trial. ...
Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy [0.03%]
英美两国进行的ESOPEC III期临床试验：围手术期化疗与新辅助放化疗治疗食管腺癌术后复发模式的比较
Jens Hoeppner,Claudia Schmoor,Thomas Brunner et al.
Jens Hoeppner et al.
The ESOPEC trial showed that perioperative chemotherapy with fluorouracil (FU)/leucovorin/oxaliplatin/docetaxel (FLOT) improved survival in patients with nonmetastatic esophageal adenocarcinoma compared with preoperative chemoradiotherapy w...
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE) [0.03%]
RP1联合纳武利尤单抗治疗晚期anti-PD-1失败的黑色素瘤患者(Ignite)
Michael K Wong,Mohammed M Milhem,Joseph J Sacco et al.
Michael K Wong et al.
Purpose: Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is an HSV-1-based oncolytic immunotherapy, here evaluated in combination with nivolum...
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study [0.03%]
Lisocabtagene maraleucel与标准疗法治疗二线复发/难治性大B细胞淋巴瘤：来自随机III期TRANSFROM研究的3年随访数据
Manali Kamdar,Scott R Solomon,Jon Arnason et al.
Manali Kamdar et al.
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for ...